Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
AIDS and Behavior
|
May 9, 2015
Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients
Diana Hernández, Daniel J Feaster, Lauren Gooden, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Frank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults
Joel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 16, 2013
Linkage to HIV care in San Francisco: implications of measure selection
Moupali Das, Katerina A Christopoulos, Dara Geckeler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 11, 2013
Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco
Glenn-Milo Santos, Phillip O Coffin, Moupali Das, et al.
AIDS and Behavior
|
February 11, 2014
Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial
Phillip O Coffin, Glenn-Milo Santos, Grant Colfax, et al.
Drug and Alcohol Dependence
|
March 20, 2014
Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men
Glenn-Milo Santos, Phillip O Coffin, Eric Vittinghoff, et al.
The Lancet. HIV
|
October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Franco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
Gregory D Huhn, Pablo Tebas, Joel Gallant, et al.
The Journal of Infectious Diseases
|
November 16, 2023
HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo
Paul N Zivich, Stephen R Cole, Jessie K Edwards, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
AIDS and Behavior
|
May 9, 2015
Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients
Diana Hernández, Daniel J Feaster, Lauren Gooden, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Frank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults
Joel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 16, 2013
Linkage to HIV care in San Francisco: implications of measure selection
Moupali Das, Katerina A Christopoulos, Dara Geckeler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 11, 2013
Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco
Glenn-Milo Santos, Phillip O Coffin, Moupali Das, et al.
AIDS and Behavior
|
February 11, 2014
Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial
Phillip O Coffin, Glenn-Milo Santos, Grant Colfax, et al.
Drug and Alcohol Dependence
|
March 20, 2014
Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men
Glenn-Milo Santos, Phillip O Coffin, Eric Vittinghoff, et al.
The Lancet. HIV
|
October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Franco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
Gregory D Huhn, Pablo Tebas, Joel Gallant, et al.
The Journal of Infectious Diseases
|
November 16, 2023
HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo
Paul N Zivich, Stephen R Cole, Jessie K Edwards, et al.
Page
of 7